Equities research analysts expect AstraZeneca plc (NYSE:AZN) to announce $6.63 billion in sales for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for AstraZeneca’s earnings. The lowest sales estimate is $6.55 billion and the highest is $6.71 billion. AstraZeneca reported sales of $6.42 billion in the same quarter last year, which would suggest a positive year over year growth rate of 3.3%. The firm is scheduled to issue its next quarterly earnings results on Thursday, February 13th.
According to Zacks, analysts expect that AstraZeneca will report full year sales of $24.07 billion for the current fiscal year, with estimates ranging from $23.79 billion to $24.43 billion. For the next financial year, analysts anticipate that the business will post sales of $26.36 billion, with estimates ranging from $25.66 billion to $27.11 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for AstraZeneca.
AstraZeneca (NYSE:AZN) last announced its quarterly earnings data on Thursday, October 24th. The company reported $0.50 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.45 by $0.05. AstraZeneca had a return on equity of 38.63% and a net margin of 8.42%. The company had revenue of $6.13 billion during the quarter, compared to analysts’ expectations of $6.07 billion. During the same quarter last year, the company earned $0.71 EPS. AstraZeneca’s revenue for the quarter was up 14.8% compared to the same quarter last year.
A number of research firms recently commented on AZN. Cowen reiterated an “outperform” rating and set a $55.00 price target (up previously from $48.00) on shares of AstraZeneca in a report on Monday, December 2nd. Leerink Swann began coverage on AstraZeneca in a report on Friday, November 22nd. They set an “outperform” rating and a $57.00 price target for the company. DZ Bank cut AstraZeneca from a “hold” rating to a “sell” rating in a report on Tuesday, September 3rd. Argus lifted their price target on AstraZeneca to $50.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Finally, Zacks Investment Research cut AstraZeneca from a “strong-buy” rating to a “hold” rating and set a $49.00 price target for the company. in a report on Thursday, October 3rd. Four investment analysts have rated the stock with a sell rating, five have assigned a hold rating and twelve have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $48.72.
AstraZeneca stock traded up $0.06 during midday trading on Monday, reaching $47.68. 2,477,478 shares of the company’s stock were exchanged, compared to its average volume of 4,042,849. AstraZeneca has a 52 week low of $35.30 and a 52 week high of $49.22. The company has a debt-to-equity ratio of 1.29, a quick ratio of 0.70 and a current ratio of 0.92. The firm has a market cap of $125.10 billion, a price-to-earnings ratio of 27.56, a P/E/G ratio of 1.67 and a beta of 0.47. The stock’s 50-day simple moving average is $47.34 and its 200 day simple moving average is $43.55.
In related news, major shareholder Plc Astrazeneca acquired 425,000 shares of the business’s stock in a transaction on Monday, October 7th. The stock was purchased at an average cost of $19.00 per share, for a total transaction of $8,075,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
A number of hedge funds have recently modified their holdings of the business. Resources Management Corp CT ADV acquired a new stake in AstraZeneca during the third quarter worth approximately $49,000. Squarepoint Ops LLC lifted its position in AstraZeneca by 48.6% during the third quarter. Squarepoint Ops LLC now owns 150,286 shares of the company’s stock worth $6,698,000 after acquiring an additional 49,157 shares during the last quarter. Voloridge Investment Management LLC lifted its position in AstraZeneca by 49.6% during the third quarter. Voloridge Investment Management LLC now owns 339,200 shares of the company’s stock worth $15,118,000 after acquiring an additional 112,534 shares during the last quarter. Integrated Wealth Concepts LLC lifted its position in AstraZeneca by 39.6% during the third quarter. Integrated Wealth Concepts LLC now owns 11,132 shares of the company’s stock worth $496,000 after acquiring an additional 3,158 shares during the last quarter. Finally, Parametric Portfolio Associates LLC lifted its position in AstraZeneca by 7.9% during the third quarter. Parametric Portfolio Associates LLC now owns 2,987,152 shares of the company’s stock worth $133,137,000 after acquiring an additional 217,690 shares during the last quarter. Hedge funds and other institutional investors own 17.50% of the company’s stock.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Story: Why do earnings reports matter?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.